Your browser doesn't support javascript.
loading
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari, Michel D; Diener, Hans Christoph; Ning, Xiaoping; Galic, Maja; Cohen, Joshua M; Yang, Ronghua; Mueller, Matthias; Ahn, Andrew H; Schwartz, Yael Carmeli; Grozinski-Wolff, Melissa; Janka, Lindsay; Ashina, Messoud.
Affiliation
  • Ferrari MD; Leiden University Medical Centre, Leiden, Netherlands. Electronic address: m.d.ferrari@lumc.nl.
  • Diener HC; Universitätsklinikum Essen, Essen, Germany.
  • Ning X; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Galic M; Teva Pharmaceuticals, Amsterdam, Netherlands.
  • Cohen JM; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Yang R; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Mueller M; Teva Pharmaceuticals, Amsterdam, Netherlands.
  • Ahn AH; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Schwartz YC; Teva Pharmaceutical Industries, Petah Tikva, Israel.
  • Grozinski-Wolff M; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Janka L; Teva Pharmaceuticals Industries, Frazer, PA, USA.
  • Ashina M; Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Lancet ; 394(10203): 1030-1040, 2019 09 21.
Article in En | MEDLINE | ID: mdl-31427046

Full text: 1 Database: MEDLINE Main subject: Migraine Disorders / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Migraine Disorders / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article